Background: Calcific aortic valve stenosis (CAVS) is the most common valvular defect in developed countries. Unlike mitral valve prolapse, there is no demonstration that a familial factor could play a role in the occurrence of this disease. The aim of this study was to demonstrate a familial aggregation for CAVS.
Methods And Results: We used the files of 2527 consecutive patients operated on for CAVS in our institution between 1992 and 2002 to map the distribution of operated CAVS in the western part of France. In a second step, we investigated clinically and genealogically the clusters with the highest rates of operated CAVS to detect familial forms of the disease. The geographic distribution of CAVS is highly heterogeneous, with an average frequency of operated CAVS of 1.13 per 1000 inhabitants but up to 9.38 per 1000 in specific parishes. A screening of the population from the parishes with the highest rate of operated CAVS allowed us to identify 5 families with > or =3 sibs affected by CAVS. A large genealogical analysis performed in one of these families allowed us to link 48 patients who derived from 34 nuclear families. Genealogical information could be traced to a common ancestor within 13 generations.
Conclusions: Identification of clusters and large families affected by a classic form of CAVS demonstrates a familial aggregation for this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.105.569467 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A CAV-Lead speed advice approach considering local spatiotemporal traffic state near bottlenecks.
Accid Anal Prev
December 2024
School of Systems Science, Beijing Jiaotong University, Beijing, China; School of Economics and Management, Beijing Jiaotong University, Beijing, China.
Bottlenecks of the freeway generated especially by traffic accidents or temporary work zones contribute to significant reductions in system throughput and hinder the efficient traffic operations. It is imperative to take proactive measures to improve traffic state. With the rapid advancements in intelligent transportation, connected and autonomous vehicles (CAVs) have attracted much attention by its speculated capabilities in improving traffic safety and well-organized operational coordination.
View Article and Find Full Text PDFRole of CD34 in calcification of human aortic valve interstitial cells from patients with aortic valve stenosis.
J Pharmacol Sci
November 2024
Department of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan. Electronic address:
Article Synopsis
- The study investigates the role of CD34 in human aortic valve interstitial cells (HAVICs) related to calcified aortic valve stenosis (CAVS), highlighting the complexity of calcification factors involved.
- It was found that CD34-negative HAVICs are more sensitive to calcification stimuli and that the expression of tenascin X (TNX) mRNA significantly decreases in these cells.
- The research suggests that CD34 acts as an inhibitory regulator against valve calcification, particularly by counteracting the effects of inflammatory cytokines like TNF-α and IL-1β, which lower CD34 expression and contribute to increased calcification.
Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization.
Rev Cardiovasc Med
August 2024
China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, 100029 Beijing, China.
Background: Proprotein convertase subtilisin/kexin type 9 (), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (), cholesteryl ester transfer protein () and apolipoprotein C3 () are pivotal regulators of lipid metabolism, with licensed drugs targeting these genes. The use of lipid-lowering therapy via the inhibition of these genes has demonstrated a reduction in the risk of cardiovascular disease. However, concerns persist regarding their potential long-term impact on aortic diseases and calcific aortic valve disease (CAVS).
View Article and Find Full Text PDFLipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis.
JAMA Cardiol
September 2024
Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
Article Synopsis
- There are currently no drugs available to slow the progression of aortic stenosis, and while plasma lipoprotein(a) levels may predict its onset, their role in disease progression is debated.
- A study involving 710 patients from Canada and the UK examined the relationship between plasma lipoprotein(a) concentrations and hemodynamic changes in aortic stenosis.
- Results showed that patients with higher lipoprotein(a) levels experienced significantly faster progression in peak aortic jet velocity and mean transvalvular gradient, suggesting that elevated lipoprotein(a) may contribute to worse outcomes in aortic stenosis patients.
Enoyl coenzyme a hydratase 1 attenuates aortic valve calcification by suppressing Runx2 via Wnt5a/Ca pathway.
J Cell Commun Signal
June 2024
The morbidity and death rates of calcified aortic valves|calcific aortic valve (CAV) disease (CAVD) remain high for its limited therapeutic choices. Here, we investigated the function, therapeutic potential, and putative mechanisms of Enoyl coenzyme A hydratase 1 (ECH1) in CAVD by various in vitro and in vivo experiments. Single-cell sequencing revealed that ECH1 was predominantly expressed in valve interstitial cells and was significantly reduced in CAVs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!